BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Acarbose (Glucobay, BAYG5421)
Drug: Placebo

First Posted Date: 2009-11-09

Last Posted Date: 2010-12-28

Lead Sponsor: Bayer

Target Recruit Count: 204

Registration Number: NCT01010100

Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers

Phase 1

Completed

Conditions: Diagnostic Imaging

Interventions: Drug: F-18 DPA-714 (BAY85-8102)

First Posted Date: 2009-11-06

Last Posted Date: 2013-07-31

Lead Sponsor: Bayer

Target Recruit Count: 22

Registration Number: NCT01009359

Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease

Phase 1

Completed

Conditions: Stenotic Femoro-popliteal Arteries
Atherosclerosis
Peripheral Arterial Disease
Occluded Femoro-popliteal Arteries

Interventions: Device: Paclitaxel-coated balloon catheter angioplasty

First Posted Date: 2009-11-04

Last Posted Date: 2023-09-21

Lead Sponsor: Bayer

Target Recruit Count: 14

Registration Number: NCT01007578

Locations: 🇩🇪
Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)

Phase 3

Completed

Conditions: Human Experimentation

Interventions: Drug: Prevacid®
Drug: Zegerid

First Posted Date: 2009-11-01

Last Posted Date: 2015-03-11

Lead Sponsor: Bayer

Target Recruit Count: 63

Registration Number: NCT01005719

A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)

Phase 2

Completed

Conditions: Pneumonia

Interventions: Drug: Amikacin (BAY41-6551)
Drug: Placebo

First Posted Date: 2009-10-30

Last Posted Date: 2011-04-08

Lead Sponsor: Bayer

Target Recruit Count: 69

Registration Number: NCT01004445

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: BAY73-4506

First Posted Date: 2009-10-28

Last Posted Date: 2015-04-03

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT01003015

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Phase 1

Completed

Conditions: Dietary Fats
Pharmacokinetics

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2009-10-27

Last Posted Date: 2013-05-23

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT01002378

Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)

Phase 3

Completed

Conditions: Sun Protection

Interventions: Drug: Standard SPF 4 Sunscreen

First Posted Date: 2009-10-27

Last Posted Date: 2015-03-11

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT01001975

Silica Gel Fiber Wound Dressing for Chronic Venous Leg Ulcers

Phase 2

Terminated

Conditions: Venous Ulcer

Interventions: Device: Silica Gel Fiber
Device: Standard-of-Care

First Posted Date: 2009-10-20

Last Posted Date: 2015-07-14

Lead Sponsor: Bayer

Target Recruit Count: 121

Registration Number: NCT00998673

Avelox in Complicated Skin and Skin Structure Infections

Completed

Conditions: Skin Diseases, Bacterial

Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039)

First Posted Date: 2009-10-20

Last Posted Date: 2012-11-16

Lead Sponsor: Bayer

Target Recruit Count: 6127

Registration Number: NCT00997997

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy